[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632020":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":35,"locations":41,"responsibleParty":60,"collaborators":26,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":26,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":90,"whyStopped":26,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Punjab Institute of Cardology","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Dual Therapy Group","EXPERIMENTAL","Participants will receive dual lipid-lowering therapy consisting of atorvastatin and ezetimibe for a duration of 6 weeks.",[13,14],"Drug: Atorvastatin 40 Mg Oral Tablet","Drug: Ezetimibe 10 mg",{"label":16,"type":10,"description":17,"interventionNames":18},"Triple Therapy Group","Participants will receive triple lipid-lowering therapy consisting of atorvastatin, ezetimibe, and bempedoic acid for a duration of 3 months.",[13,14,19],"Drug: Bempedoic Acid 180 MG Oral Tablet",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Atorvastatin 40 Mg Oral Tablet","Atorvastatin administered orally once daily as part of lipid-lowering therapy",[9,16],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Ezetimibe 10 mg","Ezetimibe administered orally once daily to reduce cholesterol absorption",[9,16],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"Bempedoic Acid 180 MG Oral Tablet","Bempedoic acid administered orally once daily as an adjunct lipid-lowering agent",[16],[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Usman Sajid, MBBS, Resident cardiologist","CONTACT","+923028169194","thextremefire@gmail.com",[42],{"facility":43,"status":26,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Punjab Institute of Cardiology","Lahore","Punjab Province","56000","Pakistan","PK",{"type":50,"coordinates":51},"Point",[52,53],74.35071,31.558,{"lat":53,"lon":52},[56,58],{"name":57,"role":38,"phone":39,"phoneExt":26,"email":40},"Usman Sajid, MBBS",{"name":57,"role":59,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":59,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Usman Sajid","Principal Investigator","100632020","phase-4-triple-vs-dual-lipid-lowering-therapy-for-ldl-c-reduction-in-acute-coronary-syndrome-100632020",false,"NCT07508254","Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome","Triple (Atorvastatin, Ezetimibe, and Bempedoic Acid) Versus Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome: A Randomized Controlled Trial","TLD-ACS","Inclusion Criteria:\n\n1. Must be older than 18 years, male or female.\n2. Diagnosis of ACS (Acute Coronary Syndrome) is confirmed when hospitalized.\n3. Eligible for high-intensity statin therapy (atorvastatin)\n4. Patients can provide written informed consent.\n5. Patients will be eager to cooperate with study drugs and follow-up visits.\n\nExclusion Criteria:\n\n1. Intolerance or hypersensitivity to study drugs.\n2. Liver or ALT\u002FAST greater than three times the upper normal.\n3. Renal dysfunction: estimated glomerular filtration rate (eGFR) less than 30 mL\u002Fmin\u002F1.73 m².\n4. Gout with frequent bouts or severe hyperuricemia.\n5. Pregnancy\u002Flactation","ALL","18 Years",{"count":74,"type":75},120,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol levels in adults with acute coronary syndrome. It will also assess the safety of the treatment.\n\nThe main questions it aims to answer are:\n\n* Does triple therapy result in greater reduction in LDL-C compared to dual therapy?\n* What adverse effects occur in participants receiving triple therapy?\n\nResearchers will compare triple therapy to dual therapy to determine its effectiveness in lowering LDL-C levels.\n\nParticipants will:\n\n* Receive either dual or triple lipid-lowering therapy for 3 months\n* Attend regular follow-up visits for clinical assessment and laboratory testing\n* Undergo lipid profile evaluation at baseline and at the end of the study",[81,82],"Acute Coronary Syndromes (ACS)","Hypercholesterolemia",[84,85,86,87,88,89],"LDL-C Reduction","Statins","Ezetimibe","Bempedoic Acid","Randomized Controlled Trial","Acute Coronary Syndrome","NOT_YET_RECRUITING","2026-04-03",{"date":93,"type":94},"2026-04-09","ACTUAL",{"date":96,"type":75},"2026-05-01",{"date":98,"type":75},"2026-10-31",{"name":5,"class":6},1]